Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine for molecular relapse of pediatric acute myeloid leukemia
NL-OMON52770Phase 2Completed
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in acute myeloid leukemia (AML), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Primary endpoint based on molecular response. Started Jun 2020; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON52770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52770.